References of "Chapelle, Jean-Paul"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHuman anti-animal antibodies interference in the Siemens Immulite chemiluminescent insulin immuno-assay: about one case
Cavalier, Etienne ULg; Huberty, Véronique; Carlisi, Ignazia ULg et al

in Clinica Chimica Acta (2011), 412(7-8), 668-669

Detailed reference viewed: 56 (10 ULg)
Full Text
Peer Reviewed
See detailLifestyle Behaviours and Plasma Vitamin C and β-Carotene Levels from ELAN Population (Liège, Belgium)
PINCEMAIL, Joël ULg; Vanbelle, Sophie ULg; Degrune, Fabien et al

in Journal of Nutrition and Metabolism (2011), 2011

Several factors, including fruit and vegetables intakes, have been shown to significantly influence the plasma concentrations of the two antioxidants vitamin C and β-carotene. Deficiency levels of 6 mg/L ... [more ▼]

Several factors, including fruit and vegetables intakes, have been shown to significantly influence the plasma concentrations of the two antioxidants vitamin C and β-carotene. Deficiency levels of 6 mg/L (34.2 μM) for vitamin C and of 0.22 mg/L (0.4 μM) for β-carotene have been suggested below which cardiovascular risk might be increased. The present study performed on 897 presumably healthy subjects aged 40–60 years aimed to examine how modifiable lifestyle factors may be related to vitamin C and/or β-carotene deficiency. Gender, smoking, lack of regular physical activity and of daily fruit consumption (≥2/day), and social status (in particular, unemployment) were found to be significant risk factors for vitamin C deficiency. For β-carotene deficiency, the same factors were identified except social status; moreover, overweight and OC use in women were also found to have a deleterious effect. For non exposed subjects, the probability of developing vitamin C deficiency was 4% in men and 2.4% in women. This probability increased to 66.3% for men and to 44.3% for women (and even to 50.4% under OC use), when all risk factors were present. For β-carotene deficiency, the corresponding probabilities were equal to 29.7% in men and 13.7% in women (no risk factor present), and to 86.1% for men and 69.9% (91.6% for OC use) for women (all factors present), respectively [less ▲]

Detailed reference viewed: 115 (41 ULg)
Full Text
Peer Reviewed
See detailSeasonal variations in vitamin D levels in melanoma patients : a single-centre prospective pilot comparative study
FAILLA, Valérie ULg; CAVALIER, Etienne ULg; EL HAYDERI, Lara ULg et al

in Journal of the European Academy of Dermatology & Venereology (2011)

Background: More than 90% of vitamin D synthesis is dependent on UV exposure. Photosensitive disorders such as lupus erythematosus, protoporphyria and xeroderma require strict sun avoidance, and vitamin D ... [more ▼]

Background: More than 90% of vitamin D synthesis is dependent on UV exposure. Photosensitive disorders such as lupus erythematosus, protoporphyria and xeroderma require strict sun avoidance, and vitamin D deficiency has been demonstrated in these patients. Melanoma patients are also instructed to avoid sun exposure and may hence be expected to be vitamin D deficient. Materials and method : Winter and summer vitamin D levels were compared in a group of melanoma patients (n=61) and age- and phototype-matched controls (n=53) without photosensitive disorders. Results : Oral supplementary vitamin D intake was reported in 32.7% of the melanoma patients and in 15.1 % in the control group. Despite oral supplementation, only 25% of the melanoma patients and the controls presented with vitamin D levels of 30 ng/mL or higher. In non-supplemented subjects in the melanoma and control groups, respectively, mean winter vitamin D levels were below the recommended threshold at 12,6 ng/mL vs 13.2 ng/mL, respectively, but not statistically different. These values increased significantly in both groups during the summer to 24.6 and 23.8 ng/mL respectively. Conclusion: Unexpected, significant increases in vitamin D levels were seen in melanoma patients during summer, suggesting non-adherence with photoprotective measures and reflecting a heliophilic behaviour. Vitamin D supplementation is recommended in melanoma patients during both winter and summer. [less ▲]

Detailed reference viewed: 35 (2 ULg)
Full Text
Peer Reviewed
See detailValidation of the Abbott Architect 25(OH)-vitamin D assay
CAVALIER, Etienne ULg; CARLISI, Ignazia ULg; BEKAERT, Anne-Catherine ULg et al

in Clinical Chemistry & Laboratory Medicine (2011), 49(s1), 418

Detailed reference viewed: 139 (3 ULg)
Full Text
Peer Reviewed
See detailCross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples.
CAVALIER, Etienne ULg; WALLACE, A. Michael; CARLISI, Ignazia ULg et al

in Clinical chemistry and laboratory medicine : CCLM / FESCC (2011), 49(3), 555-8

Detailed reference viewed: 42 (6 ULg)
Full Text
Peer Reviewed
See detailAnalytical validation of the Liaison Calcitonin_II-Gen (DiaSorin)
Cavalier, Etienne ULg; Carlisi, Ignazia ULg; Bekaert, Anne-Catherine ULg et al

in Clinical Chemistry & Laboratory Medicine (2011), 49(2), 271-275

Detailed reference viewed: 25 (2 ULg)
Full Text
See detailAnalyse morphoconstitutionnelle des lithiases
Gadisseur, Romy ULg; Chapelle, Jean-Paul ULg; Cavalier, Etienne ULg

Conference (2010, November 18)

Detailed reference viewed: 10 (0 ULg)
Full Text
See detailNew technologies in allergology, Workshop
Gadisseur, Romy ULg; Chapelle, Jean-Paul ULg; Cavalier, Etienne ULg

Conference (2010, October)

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailEstimate of total salt intake in two regions of Belgium through analysis of sodium in 24h urine samples
Vandevijvere, Stéphanie; De Keyzer, W.; Chapelle, Jean-Paul ULg et al

in European Journal of Clinical Nutrition (2010)

Objectives: To evaluate total salt intake in the adult population through an analysis of sodium in 24-h urine samples in two regions of Belgium. Methods: Urine samples were collected over 24 h from ... [more ▼]

Objectives: To evaluate total salt intake in the adult population through an analysis of sodium in 24-h urine samples in two regions of Belgium. Methods: Urine samples were collected over 24 h from participants and they had to complete a specific questionnaire about salt intake afterwards. Sodium and creatinine concentrations were analysed in these samples. Subjects: The target population comprised adults aged 45–65 years in the region of Ghent and Liege. A total of 123 and 157 volunteers from Ghent and Liege, respectively, were included in the study. Results: The mean creatinine level in Flanders (n=114) amounted to 0.173±0.035 mmol/kg/day, whereas in the Walloon region (n=135) it amounted to 0.161±0.036 mmol/kg/day, after the exclusion of subjects with incomplete urine collection. Intake of sodium in Flanders (n=114) was 4.29±1.29 g/day, whereas in the Walloon region (n=135) it was 3.94±1.44 g/day. In both regions, sodium intake in men was higher than in women. Conclusion: Salt intake was more or less twice as high as the recommended intake. Salt intake as estimated from 24-h urine collections is substantially higher than that previously calculated on the basis of food consumption data. A salt reduction programme for Belgium is primordial. [less ▲]

Detailed reference viewed: 26 (9 ULg)
Full Text
Peer Reviewed
See detailThe Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma.
Cavalier, Etienne ULg; Daly, Adrian ULg; Betea, Daniela ULg et al

in Journal of Clinical Endocrinology and Metabolism (2010), 95

Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is ... [more ▼]

Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is recognized by third-generation but not by second-generation PTH immunoassays. In normal individuals, the third-generation to second-generation PTH ratio should be less than 1. Objective: Our objective was to study the utility of the third-generation to second-generation PTH ratio as a means of distinguishing PCa patients (n = 24) from control groups with and without disorders of calcium secretion, including patients on renal hemodialysis (n = 74), postrenal transplantation (n = 60), and primary hyperparathyroidism (PHP; n = 30). Setting and Design: We conducted a retrospective, laboratory-based study at tertiary referral academic centers. Results: The mean third-generation to second-generation ratio was 0.58 ± 0.10 in the dialysis patients, 0.54 ± 0.10 in the renal transplant group, 0.54 ± 0.12 in the elderly healthy patients, and 0.68 ± 0.11 in the PHP group. All 245 of these patients presented a PTH third-generation to second-generation ratio of less than 1. In contrast, we observed an inverted third-generation to second-generation PTH ratio of more than one in 20 PCa patients, whereas only four PCa patients had a normal ratio of less than 1. Conclusions: An inverted third-generation to second-generation PTH ratio occurred in the majority of patients with advanced PCa and was absent in all 245 relevant controls. A third-generation to second-generation PTH ratio higher than 1 had a sensitivity of 83.3% and a specificity of 100% among PHP patients as a marker for PCa. This ratio may be useful to identify patients with PCa earlier and to detect patients either at risk of developing PCa or those in whom recurrence is taking place. [less ▲]

Detailed reference viewed: 68 (9 ULg)
Full Text
Peer Reviewed
See detailThe repressing function of the oncoprotein BCL-3 requires CtBP while its polyubiquitination and degradation involve the E3 ligase TBLR1
Keutgens, Aurore ULg; Shostak, Kateryna ULg; Close, Pierre ULg et al

in Molecular & Cellular Biology (2010), 30

The nuclear and oncogenic BCL-3 protein activates or represses gene transcription when bound to NF-kB proteins p50 and p52, yet the molecules that specifically interact with BCL-3 and drive BCL-3-mediated ... [more ▼]

The nuclear and oncogenic BCL-3 protein activates or represses gene transcription when bound to NF-kB proteins p50 and p52, yet the molecules that specifically interact with BCL-3 and drive BCL-3-mediated effects on gene expression remain largely uncharacterized. Moreover, GSK3-mediated phosphorylation of BCL-3 triggers its degradation through the proteasome, but the proteins involved in this degradative pathway are poorly characterized. Biochemical purification of interacting partners of BCL-3 led to the identification of CtBP as a molecule required for the ability of BCL-3 to repress gene transcription. CtBP is also required for the oncogenic potential of BCL-3 and for its ability to inhibit UV-mediated cell apoptosis in keratinocytes. We also defined the E3 ligase TBLR1 as a protein involved in BCL-3 degradation through a GSK3-independent pathway. Thus, our data demonstrate that the LSD1/CtBP complex is required for the repressing abilities of an oncogenic IkB protein, and they establish a functional link between the E3 ligase TBLR1 and NF-kB. [less ▲]

Detailed reference viewed: 81 (23 ULg)
Full Text
Peer Reviewed
See detailAssessment of high sensitive troponin T and I immunoassays in patients with acute chest
Le Goff, Caroline ULg; Garweg, Christophe ULg; Laurent, Terry et al

in Clinical Chemistry (2010, July), 56(S6), 127

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation ... [more ▼]

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation, they are used to differentiate unstable angina from non ST-segment elevation myocardial infarction (NSTEMI). Recently, troponin assays with higher analytical sensitivities became available to enable the detection of minor myocardial damage and identify individuals at higher risk for ACS. As a result of its high tissue-specificity, cardiac troponin T and I are cardio-specific, highly sensitive markers for myocardial damage. The aim of this study was to evaluate the new higher sensitive troponin (T and I) in patients with stable angina and acute chest pain without ST-segment elevation. Methods: Sixty subjects (mean age : 65.5± 11 years), were included: 20 healthy controls, 20 patients with stable angina, 9 with unstable angina (troponin-) and 18 patients with NSTEMI myocardial infarction (troponin+). The protocol was approved by the ethic committee of the University of Liège (Belgium). High sensitive troponin T (hsTnT) determination was realized on heparin plasma by electrochemiluminescence immunoassay on Modular E (Roche Diagnostic). Troponin I II (TnI II) is a chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin-I in heparine plasma on the ARCHITECT i System (Abbott Diagnostic). The lower detection limit of these assays was 0.005μg/L for hsTnT and 0.01μg/L for TnI II. Stastistical analysis was performed using t test. P value <0.05 was considered significant. Results: HsTNT levels were 0.003(0.003, 0.004) [median baseline (1st, 3rd quartile)]ng/ml in controls, 0.0075 (0.00475, 0.014) ng/ml in stable angina, 0.011(0.006, 0.012) ng/ml in unstable angina and 0.3715 (0.1795, 1.00725) ng/ml in NSTEMI ACS. TnI II levels were 0 (0, 0.001) ng/ml in controls and in patients with stable angina, 0.07 (0.005, 0.014) ng/ml in unstable angina and 1.4475 (0.0407, 2.656) ng/ml in NSTEMI. HsTNT and TnI II levels were significantly increased in NSTEMI as compared to control subjects, patients with stable and unstable angina. TnI II levels were also increased in unstable angina as compared to controls. Conclusion: In our population, TnI II was more sensitive than hsTNT to detect minor myocardial damage in patients with unstable angina as compared to controls. Therefore, future studies will have to determine whether TnI II might contribute to better risk stratification and treatment strategy in this group of patients. [less ▲]

Detailed reference viewed: 144 (16 ULg)
Full Text
Peer Reviewed
See detailDoes echocardiographic stress test induced release of hsTnT and TnI II?
Le Goff, Caroline ULg; Laurent, Terry; Garweg, Christophe ULg et al

in Clinical Chemistry (2010, July), 56(S6), 128

Background: Cardiac troponins (cTn) are considered as the best biomarkers for detection of myocardial cell injury. In this study, cTnT and cTnI were measured by new commercially available high-sensitive ... [more ▼]

Background: Cardiac troponins (cTn) are considered as the best biomarkers for detection of myocardial cell injury. In this study, cTnT and cTnI were measured by new commercially available high-sensitive methods in patients undergoing brief exercise- or pharmacologicinduced stress. Our aim was to compare cTnT and cTnI levels before and after the stress tests, in the patients with or without reversible ischemia. Materials and Methods: Fifty patients (28 men and 22 women) underwent an echographic stress test (ST) for suspected ischemic heart disease. Of these 50 patients, 28 received pharmacological ST (dobutamine injection) and 22 dynamic ST (bicycle exercise). The patients were subdivided into two groups according to the presence or absence of documented transient reversible ischemia: 14 with reversible ischemia ( mean age: 67.71±9.66 y) and 36 without ischemia ( mean age: 63.17±11.72 y). In all patients, cTnT and cTnI concentrations were measured by high sensitive methods (hsTnT, Roche Diagnostics and TnI II, Abbott Diagnostics) on heparin plasma immediately before (T0) and after ST (T1).The lower detection limit of these assays was 0.005μg/L for hsTnT and 0.01μg/L for TnI II. The protocol was approved by the ethics committee of the University of Liège (Belgium). All patients gave informed consent. All statistical analyses were performed using Medcalc version 8.1 for Windows. P value <0.05 was regarded as statistically significant. Results: There was no significant difference between hsTnT concentrations at T0 and T1, neither in the whole patient group, nor in the subgroups of subjects who received pharmacological ST or dynamic ST. The same was true for TnI II. Although there was no change in hsTnT levels during test in ischemic and in non ischemic patients, the latter tend to demonstrate higher median T0 levels (25th, 75th percentiles) than the others [0.011 (0.007, 0.029) vs 0.007 (0.0047, 0.1125) ng/ml, p=0.09]. They also showed higher median T1 levels [0.014 (0.065, 0.03) vs 0.007 (0.003, 0.0102) ng/ml, p=0.08]. Higher TnI II levels were also recorded in ischemic patients as compared to non ischemic patients at T0[ 0.014 (0.0072; 0.0265) vs 0.005 (0.003; 0.01) ng/ml, p=0.08] and T1[ 0.013 (0.0085- 0.03) vs 0.006 (0.0035-0.008) ng/ml, p=0.08]. Also, TnI II levels did not change during test in both subgroups. Conclusions: Measurement of cardiac troponins by high sensitive methods did not allow to detect significant release of biomarkers from the heart during exercise-or pharmacologic-induced ST, even in patients who demonstrated reversible myocardial ischemia. The type of test – pharmacological or dynamic - was without effect. The patients with induced transient ischemia had however higher troponin T and I levels at baseline, this difference remaining during test. [less ▲]

Detailed reference viewed: 102 (9 ULg)
Full Text
Peer Reviewed
See detailValidation of the ImmunoCAP ISAC
Gadisseur, Romy ULg; Blanco Catafal, Anna; Chapelle, Jean-Paul ULg et al

in Clinical Chemistry (2010, June), 56(S6), 97

Detailed reference viewed: 91 (5 ULg)
Full Text
Peer Reviewed
See detailEvaluation of Liaison Calcitonin II Gen, a new kit for Calcitonin determination
Cavalier, Etienne ULg; Carlisi, Ignazia ULg; Bekaert, Anne-Catherine ULg et al

in Clinical Chemistry (2010, June), 56(S6), 188

Detailed reference viewed: 53 (3 ULg)
Full Text
Peer Reviewed
See detailAnalytical validation of the Abbott Architect urine NGAL
Cavalier, Etienne ULg; Saarbach, D.; Bekaert, Anne-Catherine ULg et al

in Clinical Chemistry (2010, June), 56(S6), 96

Detailed reference viewed: 96 (3 ULg)